Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05265429 · ClinicalTrials.gov registry record
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
A clinical trial of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 500
- Enrollment target
- 4
- Study locations
NCT05265429: Recruiting study of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by Dana-Farber Cancer Institute.
NCT05265429 is a study of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 500 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (23% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05265429, a study of Non-Small Cell Lung Cancer and Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Primary Outcome
Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.
Conditions Studied
Interventions
- GENETIC Data and Specimen Collection
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-08-01 |
What NCT05265429 shows while recruiting
NCT05265429 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (23% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Data and Specimen Collection is the first listed.
NCT05265429 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05265429 about?
NCT05265429 is a clinical study titled "Biology of Young Lung Cancer Study: The YOUNG LUNG Study". The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
What is the current status of trial NCT05265429?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-01-01. Estimated completion is 2027-08-01.
What conditions does trial NCT05265429 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma.
What interventions are being tested in trial NCT05265429?
The interventions under investigation include: Data and Specimen Collection (GENETIC).
Who is sponsoring clinical trial NCT05265429?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05265429 being conducted?
This trial has 4 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05265429's enrollment target sits among peer trials
500 74th of 454 higher than 379 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI